| Nanocarrier system |
Agents |
Indication |
Status |
References |
| Liposome (CPX-351) |
Cytarabine + Daunorubicin |
Advanced Hematologic Cancer |
Phase II |
[144] |
| Liposome (CPX-1) |
Irinotecan + Floxuridine |
Advanced Colorectal Cancer |
Phase II |
[145] |
| Liposome (CPX-571) |
Irinotecan and Cisplatin |
Non-small-cell lung cancer |
Preclinical |
[225-227] |
| PEG- Liposome |
Topotecan + Vincristine |
Brain cancer |
Preclinical |
[138] |
| Liposome |
Topotecan + Amlodipine |
Leukemia |
Preclinical |
[228] |
| Liposome |
Vincristine + Quinacrine |
Leukemia |
Preclinical |
[229] |
| Liposome |
6-Mercaptopurine + Daunorubicin |
Leukemia |
Preclinical |
[230] |
| Liposome |
Paclitaxel + Tariquidar |
Ovarian cancer |
Preclinical |
[231] |
| Transferrin-conjugated PEGylated liposome |
Doxorubicin + Verapamil |
Leukemia |
Preclinical |
[134] |
| Trilysinoyloleylamide(TLO)-based cationic liposomes |
siMcl1+Suberoylanilidehydroxamic acid |
Cervical cancer |
Preclinical |
[126] |
| Nanolipoplex |
Taurocholate(LHT7)+ Suberoylanilidehydroxamic acid |
Oral cancer |
Preclinical |
[130] |
| Liposome |
PD0325901 +siMcl1 |
Cervical cancer |
Preclinical |
[127] |
| Liposome |
Doxorubicin+ Msurvivin T34A plasmid |
Lung carcinoma |
Preclinical |
[128] |
| Liposome |
Ceramide+ Sorafenib |
Breast Cancer |
Preclinical |
[124] |
| Liposome |
siB-Raf+ siAkt3 |
Melanoma |
Preclinical |
[64] |
| PEGylatedlipoplex |
siBcl-2-lipoplex+ S- 1(5-FU) pro-drug |
Colorectal cancer |
Preclinical |
[92] |
| RGD-modified liposomes |
Combretastatin A-4+ Doxorubicin |
Melanoma |
Preclinical |
[147] |
| Liposome |
Gemcitabine+Tamoxifen |
Breast cancer |
Preclinical |
[148] |
